Table 2 Mean change from baseline in MGC, MG-ADL and QMG scores at month 3
MG Clinical Outcomes | Descartes-08 (n = 15) | Placebo (n = 11) | |
|---|---|---|---|
MGC score | Baseline, mean (s.d.) | 16.4 (6.39) | 15.7 (3.95) |
Month 3, mean (s.d.) | 11.4 (8.57) | 13.5 (8.48) | |
Change from baseline at month 3, mean (s.d.) | −5.0 (6.67) | −2.3 (7.73) | |
Responder (≥5-point reduction), n (%) | 10 (66.7) | 3 (27.3) | |
Difference in proportions (95% CI) | 0.39 (0.01–0.77) | ||
P value | 0.0472 | ||
MG-ADL score | Baseline, mean (s.d.) | 10.5 (3.20) | 9.8 (2.79) |
Month 3, mean (s.d.) | 6.4 (4.31) | 8.2 (3.82) | |
Change from baseline at month 3, mean (s.d.) | −4.1 (3.38) | −1.6 (4.06) | |
QMG score | Baseline, mean (s.d.) | 17.3 (7.3) | 14.7 (4.03) |
Month 3, mean (s.d.) | 13.4 (7.53) | 13.2 (5.12) | |
Change from baseline at month 3, mean (s.d.) | −3.9 (4.37) | −1.5 (4.27) | |
